InMode Ltd. (NASDAQ:INMD) Shares Bought by Barclays PLC

Barclays PLC raised its stake in InMode Ltd. (NASDAQ:INMD - Free Report) by 113.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 169,630 shares of the healthcare company's stock after acquiring an additional 90,173 shares during the period. Barclays PLC owned 0.20% of InMode worth $2,876,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. National Bank of Canada FI raised its position in InMode by 6.2% in the 3rd quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company's stock valued at $169,000 after purchasing an additional 579 shares during the last quarter. Carmel Capital Partners LLC raised its holdings in shares of InMode by 6.9% in the third quarter. Carmel Capital Partners LLC now owns 11,511 shares of the healthcare company's stock valued at $195,000 after buying an additional 741 shares during the last quarter. Meritage Portfolio Management boosted its stake in shares of InMode by 9.5% during the third quarter. Meritage Portfolio Management now owns 14,765 shares of the healthcare company's stock worth $250,000 after buying an additional 1,284 shares during the period. Inspire Advisors LLC grew its holdings in shares of InMode by 9.0% during the second quarter. Inspire Advisors LLC now owns 21,433 shares of the healthcare company's stock worth $391,000 after buying an additional 1,778 shares during the last quarter. Finally, Asset Dedication LLC acquired a new position in InMode in the 2nd quarter valued at about $33,000. Hedge funds and other institutional investors own 68.04% of the company's stock.

InMode Stock Performance

InMode stock traded up $0.11 during midday trading on Wednesday, reaching $17.06. The company's stock had a trading volume of 518,368 shares, compared to its average volume of 1,296,049. InMode Ltd. has a fifty-two week low of $14.87 and a fifty-two week high of $26.80. The firm has a market capitalization of $1.43 billion, a PE ratio of 9.22 and a beta of 2.07. The stock's 50 day simple moving average is $18.29 and its 200 day simple moving average is $17.41.

Wall Street Analyst Weigh In

A number of analysts have weighed in on INMD shares. Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a research report on Thursday, October 31st. Barclays decreased their price target on InMode from $29.00 to $27.00 and set an "overweight" rating for the company in a report on Monday, October 14th. Finally, BTIG Research initiated coverage on shares of InMode in a research note on Thursday, October 17th. They issued a "buy" rating and a $25.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $22.60.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.